Beroni Group Limited New R&D Centre in High-Tech Hub in Zhuhai, China

Sydney, Australia (ABN Newswire) - Beroni Group (OTCMKTS:BNIGF) (NSX:BTG), an Australia-based diversified biopharmaceutical enterprise focused on the research, development, innovation and commercialization of therapies and products for treatment of global diseases, is pleased to announce that it has signed a contract to build a new Research & Development ("R&D") centre in the Zhuhai National High-Tech Industrial Development Zone in China. Beroni aspires to build a state-ofthe-art facility with new preclinical research labs, manufacturing process development labs, and a GMP pilot manufacturing plant.

The new R&D centre -- the first R&D site for Beroni -- will help the Company develop new drugs and medicines to cater for the vast needs of the Chinese market. To start with, the Company will occupy about 4,000 square metres (44,000 square feet) of office space for setting up the GMP plant and laboratories. Construction of the new R&D facilities is expected to be completed towards the end of the second quarter, and the entire R&D centre is expected to be ready in the second half of this year. Beroni intends to commit US$10 million to support the clinical trials in the new R&D facility. A new company, Beroni Pharmaceutical (Guangdong) Co., Ltd, has been established for this new venture with Beroni owning 80% of the entity's shares and a local investor owning the other 20% shares. The Company will bring professional staff, scientists, technicians, and support teams together into a state-of-the-art hub for innovation and development of the company's future products and services.

Beroni has a drug development pipeline focusing on oncology and immunotherapy. It is moving ahead with the Phase II clinical trial of the anti-cancer molecular drug, PENAO later this year and is scheduled to commence the clinical trials for a few cellular therapies including gamma delta T cell, DC vaccine, and protein modifier R8. It is also currently studying the use of single-domain antibodies for treatment of coronavirus diseases.

"Establishing a new R&D centre in Zhuhai will allow us to expand our R&D capabilities and accelerate our innovative pipeline," said CEO Jacky Zhang. "In the future, we plan to establish additional R&D centres around the world to advance the discovery and development of new innovative product candidates."

The Zhuhai National High-Tech Industrial Development Zone Valley, established in 1992, is one of the top biotech hubs in China and is home to hundreds of innovative biotechnology and biopharmaceutical companies. It covers an area of 139 square kilometres and boasts a convenient transportation network with the Beijing-Zhuhai Expressway, Western Guangdong Coastal Expressway and Guangzhou-Zhuhai Intercity MRT passing through the area. Ideally placed for business opportunities, the zone has the location advantage of being within the "One-Hour Economic Circle" of the Pearl River Delta.

 

About Beroni Group Limited:  

Beroni Group (NSX:BTG) (OTCMKTS:BNIGF) is an international biopharmaceutical enterprise dedicated to the innovation and commercialization of drugs and therapies to combat various global diseases such as cancer and infectious diseases. Its diversified portfolio is comprised of a US FDA approved virus diagnostic kit, an e-commerce platform for the sale of pharmaceutical products and a development pipeline targeting oncology and cell therapies. Beroni has operations in Australia, United States, China and Japan. To learn more about Beroni, please visit www.beronigroup.com.

 

 

Source:
Beroni Group Limited

 

 

Contact:
Dragon Gate Investment Partners LLC
Tel: +1(646)-801-2803
Email: BNIGF@dgipl.com

 

News Provided by ABN Newswire via QuoteMedia

BTO:CA,BTG
The Conversation (0)
Bert Dohmen

Bert Dohmen: Gold, Silver Key as Stock Market Bull Trap Looms

Bert Dohmen, founder and CEO of Dohmen Capital Research, sees physical gold and silver as key safe havens as a potential bull trap in the broad stock market plays out.

"We said we're probably going to go to a new high in a major, widely watched index like the S&P 500 (INDEXSP:.INX). It's going to be by a small amount a new high, and that's going to close the bull trap," he said.

Keep reading...Show less
Gold bars on financial charts and a notebook.

Top 5 ASX Gold Stocks of 2025

Gold continued to perform well through the second quarter of 2025, reaching a new all-time high of AU$5,425 per ounce on April 22.

The price surge has occurred amid volatile equity and financial markets since the start of the year, driven by concerns over a global trade war and escalating geopolitical tensions in the Middle East.

The rising gold price has also been supported by uncertainty over a looming debt crisis in the United States. Some investors have turned away from dollar-denominated haven assets, such as US Treasuries, in favour of precious metals like gold.

Keep reading...Show less
Gold nugget displayed on an antique balance scale with a dark background.

Meeka Metals Reports First Gold Pour at Murchison Project

Meeka Metals (ASX:MEK) has poured the first gold at its flagship Murchison project in Western Australia.

The pour happened on Tuesday (July 1), and in a Wednesday (July 2) press release, the company said the project’s production is in line with schedule, happening within 12 months of breaking ground.

Murchison sits near several multimillion-ounce gold mines and hosts a large, high-grade resource of 1.2 million ounces at 3 grams per tonne (g/t) gold on granted mining leases.

Keep reading...Show less
Sun Summit Minerals (TSXV:SMN)

Sun Summit Minerals

Keep reading...Show less

Latest Press Releases

Related News

×